Home › Trials › NCT06003426

Evaluating a new treatment for Idiopathic Pulmonary Fibrosis

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis

PHASE3 · Bristol-Myers Squibb · NCT06003426

This study is testing a new medication called BMS-986278 to see if it can help people with Idiopathic Pulmonary Fibrosis feel better and stay safe.

Quick facts

PhasePHASE3
Study typeInterventional
Enrollment1185 (estimated)
Ages40 Years and up
SexAll
SponsorBristol-Myers Squibb (industry)
Locations503 sites (Birmingham, Alabama and 502 other locations)
Trial IDNCT06003426 on ClinicalTrials.gov

What this trial studies

This study aims to assess the efficacy, safety, and tolerability of a medication called BMS-986278 in individuals diagnosed with Idiopathic Pulmonary Fibrosis (IPF). Participants will receive either the active drug or a placebo, and their responses will be monitored over the course of the trial. The study is designed for patients aged 40 and older who have been diagnosed with IPF within the last seven years. It will also consider participants who are currently on stable doses of other IPF medications.

Who should consider this trial

Good fit: Ideal candidates are adults aged 40 and older with a confirmed diagnosis of Idiopathic Pulmonary Fibrosis within the last seven years.

Not a fit: Patients with recent history of stroke or transient ischemic attack, or those exhibiting symptoms of heart failure may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could provide a new therapeutic option for patients suffering from Idiopathic Pulmonary Fibrosis.

How similar studies have performed: Other studies have shown promise with similar approaches targeting IPF, but the specific efficacy of BMS-986278 is still being evaluated.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria

* Subjects with IPF aged ≥ 40 years at the time of signing the informed consent.
* Diagnosis of IPF within 7 years prior to screening that is supported by centrally read chest high-resolution computed tomography (HRCT) obtained at screening and verification of usual interstitial pneumonia.
* If on pirfenidone or nintedanib, participants must have been on a stable dose for at least 90 days prior to screening.
* If not currently on pirfenidone or nintedanib, participants must not have received either of these medications within 28 days prior to screening.
* Women who are of childbearing potential must have a highly effective form of contraception and must provide a negative urine/serum pregnancy test.
* Men who are sexually active with women of childbearing potential agree to use male barrier contraception.

Exclusion Criteria

* History of stroke or transient ischemic attack within 3 months prior to screening.
* Participants who exhibit symptoms of heart failure at rest.
* Participants who have a current malignancy or a previous malignancy with less than 2 years free of recurrence or a biopsy that is suspicious for malignancy and the possibility of malignancy cannot be reasonably excluded following additional clinical, laboratory, or other diagnostic evaluations.
* Other protocol-defined Inclusion/Exclusion criteria apply.

Where this trial is running

Birmingham, Alabama and 502 other locations

+453 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: Idiopathic Pulmonary Fibrosis, BMS-986278, LPA1 antagonist, IPF, Pulmonary fibrosis

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.